i don't work at medtronic. i haven't been there for 12 years.id support the inversion because it was necessary d it was part of an overall strategy to expand the mission of medtronic. i think the strategy was right on the money, fulfills the mission of medtronic, adds another 5 to 6 million new patients every year and gives the company the heft to serve the global marketplace. i'm sorry that, you know, that there's these pressure on inversions and, in fact, at lot of them are coming about from activists, a number of big deals are done this way, but i think that's more a reflection of not the activist, of the tax code. i'm not optimistic it's going to get solved in the near term but wouldn't be hard to solve. we know what needs to be done and u.s. can't sit up there with 35% rates and have everyone the rest of the world below 25. other countries like germany, have come way down. i think that we've got to fix the core problems to keep america great. and that's my goal to say that the competitive edge america has scott is innovation. that's how we

ibm announcing a new unit called watson health to partner with companies like medtronic.r to explain how it works. >> all of this information is going to start to be collected and correlated. as it's correlated. we need to start using analytics on something called real-world evidence that starts to car late the data with knowledge. watson bringing the knowledge and you saw us in the lab take you through that you have to correlate that with the data. the real-world information that's being collected off these devices. apple is a piece of it. but j & j and medtronics are bringing up other pieces with medical devices. >> they haven't yet, carl, been able to bring this great marketing device, technology, into a business and show that it works to make big money. it's at risk of being the google glass of enterprise and big data. >> somebody said can they ask watson why they can't get ibm stock price up. somebody wrote in on twitter. interestingly he pointed out the amount of data we're going to be churning out as human beings, 1100 terra bytes, the equivalent of 300 million boo

bringing in the partnerships with medtronic, we can monitor data on insulin pumps.johnson & johnson, we can provide coaching to enable people to get ready for operations like hip and knee replacements, and then coach them through the their feet to wreak -- to rehabilitate after the -- the therapy to rehabilitate after the surgery. the same data can be used by researchers that are using anonymous data to look for patterns to develop new drugs and new therapy. all the information is available back to your provider, should you choose to make that available. we will bring together the whole continuum of care from the patient to the doctor to the research to the insurance companies. emily: terms of your partnership with apple, what has been the reception from apple customers to these products? how many people are using this and how are they using it? mike: we are still in the early days of connecting to the application. apple has done a very good job of managing the privacy of that information on the devices and making sure it the choice of the consumer as to whether the

jude or medtronic says.: is seen as a real living longer and we are more active that these names are not resonating as the baby boomers became of age. >> i cannot disagree with where you are going on that. >> had you looked at this? finigan it looks like of breakout on volume. i never really heard of it is really impressive seven ships up at 15 and 10 on order with 40 of the way. with liquid natural gas will have the shortage of 200 ships whoever has the ships will be in control. why is it down? i did not get a chance to see what they paid or the right cash flow so i will check into it of course, i have love the lng play i think it is a no-brainer. >> a competitor that is very similar i like it because the pricing has dropped dramatically so then this will take off. >> continental resources should i hold? >> it has been a wild ride. i think in addition to the energies based there is the situation with the ceo. what is your take? >> it is under pressure because the federal reserve does not know what it is doi

particularly things in the health care space, like abbott labs or medtronic, where valuations are still reasonable. not high-flying biotechnology stocks. steady eddies will winning out in environment where people are worrying at least a little bit about the u.s. ashley: let me bring back john. maybe you can comment on the linkedin numbers, john. as cheryl pointed out moving considerably lower in after-market trading here. seems like they had a beat on eps by one cent. they also beat on revenue. what is worrying market and investors here? >> ashley sometimes with a stock. not just what the street estimate is. sometimes analysts carry more weight than others and perhaps that is the case with linked in. linked concensus before 40% growth. so doesn't take a lot to disappoint. obviously the stock is selling off here in the after-market. cheryl: second quarter estimates. delving into the numbers, with linked in. in very high pressure market. thinked in user space and facebook and twitter. it is social media company even though it is for businesses and business individuals. that is what is goi

for a free 30-tablet trial go to cialis.com >>> coming up, former medtronics ceo bill george blastingpeltz and activists like him saying they're putting american companies at risk. mr. george will join us live to discuss his scathing op-ed. sour on apple the tech giant seeing the second stock downgrade this week. should investors be worried? fina of our halftime energy summit. paul sen ki joins us with his top players. see you in 15 or so. >> thanks. one of the biggest names in college sports speaking out against indiana's religious freedom act. jane wells is at usc to talk to pat haden. good morning, jane. >> hey, carl. thanks, pat. fight on. >> fight on. >> we have so much to talk about. never been afraid to put yourself out there. you tweeted to stand up for your son and not go to the indiana for the college football players selection meeting. could the trojans not go to south bend and play notre dame in the fall. >> we will be playing in the fall. this was just a gesture of love and support for my son whom, indeed, i love a lot and talk to him about the trip to indiana. he would a

some of the device makers medtronic, that's down about 3%. problems in health care the last few weeks just on what's going on in biotech. it's a much broader decline. some seems to be derisking going into the end of the month. that's where the profits were. some people are taking profits off the table. it makes some kind of sense here. let's move on. you talked about exxon. i want to focus on conoco. conoco reported a lot of 18 cents. that wasn't what was expected. how do you make sense of earnings for a company that has these kinds of earnings. $5.70, $5.30, 47 cents in 2015 and estimate of $2.79 for 2016. how do you have an idea what's going on? 2 you you abandon that and go to cash levels. this is probably a trough of earning. 18 cents is the bottom for conoco. that is a good sign overall. the stock has been $50, $60. i want to note the effects of dollar. i've been doing this two weeks. here is colgate palmolive. effect on revenues 15% lower. europe sales were down noticeably. almost 14%, 15%. effect on revenues was 15% decline. these are

jude is going to have a little bit of an easier time because they believe that medtronics recent marketns are going to eventually taper back off. >> speaking of currency they just reported earnings and had to take down their full year guidance because of a bigger impact from currency than expected. so yeah, it's going to be a running theme here. stock number four texas capital. this is an oil-related downgrade of a texas bank from raymond james. r.j. cutting it to an outperform from strong buy. first quarter earnings match consensus but fall short of this analyst estimates and said the provision build related to participated downgrades of energy credits may spook investors. given the energy team's recent cut in its ole forecast it is prudent to take chips off the table, especially considering this stock has done decently since february. >> yeah and there's been a lot of concern about all the bank debt that's out there. i guess one wonders with oil back above $58 a barrel if the resurgence in the price of oil, up 27% in just three months will ease some of the concerns around the banks an